Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
ORTHO-NOVUM 7/7/7-21 is an oral contraceptive tablet containing norgestimate and ethinyl estradiol in a 21-day cyclic dosing regimen. It prevents pregnancy through hormonal suppression of ovulation and is indicated for contraception in women of reproductive age. This is a foundational hormonal contraceptive product with decades of clinical use.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100); expect contracting brand team and shift toward retention and lifecycle extension initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ORTHO-NOVUM 7/7/7-21 offers stability in a mature franchise but limited growth opportunity; roles center on defending market share, managing generic competition, and optimizing reimbursement rather than innovation. This is a consolidation or transition role suitable for professionals seeking experience in late-lifecycle product management or seeking stability over upward trajectory.
Worked on ORTHO-NOVUM 7/7/7-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.